The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Introduction Thrombotic microangiopathy (TMA) is a life-threatening, albeit infrequent,
complication of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) …

Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to …

Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …

Objective To evaluate the efficacy and safety of rituximab in a randomized, double‐blind,
placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with …

The importance of the complement system in the pathogenesis of systemic lupus
erythematosus (SLE) has long been recognized. However, despite an unprecedented …

Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …

Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Abstract Objective CD40–CD40 ligand (CD40L) interactions play a significant role in the
production of autoantibodies and tissue injury in lupus nephritis. We performed an open …